1. Home
  2. GNTA vs XBIT Comparison

GNTA vs XBIT Comparison

Compare GNTA & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genenta Science S.p.A.

GNTA

Genenta Science S.p.A.

HOLD

Current Price

$1.58

Market Cap

69.4M

Sector

Health Care

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.20

Market Cap

69.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNTA
XBIT
Founded
2014
2005
Country
Italy
United States
Employees
9
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.4M
69.8M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
GNTA
XBIT
Price
$1.58
$2.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
139.7K
35.6K
Earning Date
03-24-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$2.09
52 Week High
$10.00
$3.61

Technical Indicators

Market Signals
Indicator
GNTA
XBIT
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GNTA
XBIT

About GNTA Genenta Science S.p.A.

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: